Oral administration demonstrates activity in gastrointestinal conditions despite lower systemic bioavailability, as direct mucosal exposure may contribute to therapeutic effects
Every peptide is supplied with complete Certificates of Analysis (COAs) confirming identity, purity, and batch consistency
Post-surgical recovery affecting multiple tissue types, chronic widespread inflammation, and patients whose primary complaint is global stiffness and reduced range of motion that has not improved with localized treatment all fit the TB-500 indication
The Phase 1 trial in 80 healthy volunteers demonstrated safety and tolerability across four dose levels with no serious adverse events
If you are not receiving the desired outcome with your treatment and a particular drug, consult your doctor because he may increase the dosages of the drug, recommend an addition of a second or third drug or recommend an entirely different drug type
2021, p